Share This Page
Suppliers and packagers for generic pharmaceutical drug: SALMETEROL XINAFOATE
✉ Email this page to a colleague
SALMETEROL XINAFOATE
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | SEREVENT | salmeterol xinafoate | POWDER;INHALATION | 020692 | NDA | GlaxoSmithKline LLC | 0173-0521-00 | 1 INHALER in 1 CARTON (0173-0521-00) / 60 POWDER, METERED in 1 INHALER | 1997-11-25 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: Salmeterol Xinafoate
Introduction
Salmeterol xinafoate, a long-acting beta-2 adrenergic agonist (LABA), is widely used in the management of asthma and chronic obstructive pulmonary disease (COPD). As demand for respiratory therapies increases globally, securing reliable suppliers for salmeterol xinafoate becomes critical for pharmaceutical manufacturers and healthcare providers aiming to ensure steady supply, high-quality standards, and competitive pricing. This article offers an in-depth analysis of the leading suppliers, their production capacities, market positioning, and compliance measures within the global supply chain landscape.
Overview of Salmeterol Xinafoate Production and Demand
Salmeterol xinafoate is typically synthesized by specialized chemical processes involving the creation of the salmeterol base followed by xinafoate salt formation. The drug's complex manufacturing processes necessitate advanced chemical synthesis capabilities, strict regulatory adherence, and quality controls, limiting the number of manufacturers capable of large-scale production. The growing prevalence of asthma and COPD, especially in urbanized economies, continues to propel global demand, requiring suppliers to scale operations and maintain regulatory compliance across diverse markets.
Leading Global Suppliers of Salmeterol Xinafoate
1. GlaxoSmithKline (GSK)
GSK originally developed salmeterol and holds extensive patents related to its formulation and delivery systems. Although patent protections have expired in multiple jurisdictions, GSK maintains manufacturing facilities capable of producing high-grade salmeterol xinafoate, primarily for front-line respiratory medications. The company’s tight quality controls and global distribution network make it a dominant player in the supply chain, especially in branded drugs and authorized generics.
2. Synthesis and Contract Manufacturing Organizations (CMOs)
As patent barriers have diminished, numerous CMOs have emerged as key suppliers of salmeterol xinafoate, often through licensing agreements with original developers or through independent synthesis capabilities. Prominent CMOs include Catalent, Boehringer Ingelheim, Thermo Fisher Scientific, and Dr. Reddy’s Laboratories. These organizations typically offer custom synthesis, bulk manufacturing, and relabeling services for both branded and generic formulations, ensuring supply diversification.
3. Chinese and Indian Chemical Manufacturers
India and China are central to the global supply of active pharmaceutical ingredients (APIs) due to their large manufacturing capacity and cost advantages. Notable Indian firms such as Granules India, Aurobindo Pharma, and Sun Pharmaceutical Industries produce salmeterol xinafoate API at scale, primarily for export markets. Chinese manufacturers like Huangshan Qianjie Pharmaceutical Co. and Luye Pharma also supply the API, often with rapid lead times and flexible production volumes.
4. European API Suppliers
European companies like Evonik Industries and Italian-based CordenPharma focus on high-quality API production for controlled markets, providing salmeterol xinafoate with advanced quality assurance, regulatory compliance, and GMP certification. These suppliers are favored for their strict adherence to European pharmacopoeias and regulatory standards, ensuring high purity and consistency.
Market Trends and Supply Chain Dynamics
A. Patent Expiry and Generic Competition
The expiration of GSK's patents has led to increased generic manufacturing, driving competitive pricing and widened supply options. This has resulted in a fragmented supplier landscape, reducing dependence on a single manufacturer and improving supply resilience.
B. Regulatory Harmonization and Quality Standards
Suppliers increasingly align with international regulatory standards such as EMA, FDA, and ICH guidelines. This harmonization facilitates global distribution but also necessitates ongoing compliance and certification updates, influencing supplier selection.
C. Supply Chain Disruptions and Risk Management
Recent global events, including the COVID-19 pandemic, have underscored the importance of supply chain diversification. Companies are now prioritizing multiple suppliers across regions to mitigate risks related to geopolitical tensions, manufacturing disruptions, or regulatory changes.
D. Technological Advancements in API Synthesis
Innovations in green chemistry and process optimization have improved yield, purity, and sustainability, making some suppliers more attractive due to cost efficiencies and environmental compliance.
Criteria for Supplier Selection
- Quality Assurance: Proven compliance with cGMP, ISO certification, and pharmacopoeial standards.
- Regulatory Track Record: Ability to meet diverse regional regulatory requirements.
- Manufacturing Capacity: Sufficient volume to meet current and projected demands.
- Supply Chain Reliability: Proven track record of consistent delivery and contingency planning.
- Cost Competitiveness: Competitive pricing aligned with quality standards.
- Innovative Capabilities: R&D investments for improved formulations or synthesis methods.
Future Outlook for Salmeterol Xinafoate Suppliers
The growth trajectory of salmeterol xinafoate hinges on continued innovation, regulatory adaptations, and supply chain resilience. The ongoing expansion of generic manufacturing, especially in India and China, is likely to sustain competitive pricing. Meanwhile, European and North American suppliers will focus on quality, compliance, and supply stability to serve high-end markets. Emergent players employing green chemistry and advanced synthesis techniques may disrupt traditional supply chains, introducing more sustainable options.
Strategic considerations for pharmaceutical companies include establishing diversified supplier portfolios, leveraging long-term contracts, and conducting rigorous supplier audits to ensure compliance and quality across regions.
Key Takeaways
-
The global supply of salmeterol xinafoate is distributed among major API producers in India, China, Europe, and North America, driven by patent expirations and generic proliferation.
-
Leading pharmaceutical companies like GSK maintain capacity for high-quality production, supplemented by numerous CMOs that increase supply resilience.
-
Stringent regulatory standards necessitate suppliers’ compliance with GMP, EMA, and FDA requirements for ongoing market access.
-
Supply chain diversification, technological innovations, and regulatory harmonization are vital to mitigating disruptions and controlling costs.
-
Strategic partnerships and comprehensive supplier assessments enable pharmaceutical firms to ensure consistent supply, quality, and compliance of salmeterol xinafoate.
FAQs
1. Who are the primary global suppliers of salmeterol xinafoate?
Major suppliers include GSK, Chinese and Indian API manufacturers such as Aurobindo Pharma and Sun Pharma, and European firms like Evonik Industries. Contract manufacturing organizations also play a key role.
2. How has patent expiration affected the salmeterol xinafoate supply market?
Patent expiry has increased the number of manufacturers, fostering competition, reducing prices, and diversifying supply sources, resulting in improved supply stability.
3. What regulatory considerations should buyers prioritize when sourcing salmeterol xinafoate?
Buyers should prioritize suppliers with proven compliance to cGMP, ISO standards, and relevant regulatory approvals from EMA, FDA, and other authorities.
4. What key factors determine the reliability of a salmeterol xinafoate supplier?
Production capacity, consistency in quality, regulatory compliance, supply chain robustness, and cost competitiveness are critical factors.
5. What are emerging trends impacting salmeterol xinafoate supply chains in the next decade?
Focus areas include green chemistry innovations, digitalization for traceability, increased regional manufacturing, and strategic stockpiling to mitigate disruptions.
References
- [1] European Medicines Agency (EMA). Salmeterol: Summary of Product Characteristics.
- [2] U.S. Food and Drug Administration (FDA). Approved Drug Products with Therapeutic Equivalence Evaluations.
- [3] MarketResearch.com. Global Respiratory Drugs Market Analysis.
- [4] IQVIA. Pharmaceutical Supply Chains & Emerging Trends.
- [5] Industry Reports. API Manufacturing and Supply Chain Dynamics.
More… ↓
